Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

Search
Advanced Search
OPEN ACCESS
mobile search button mobile menu button

Articles

Page Path
HOME > Cancer Res Treat > Volume 46(2); 2014 > Article
Special Article Prediction of Cancer Incidence and Mortality in Korea, 2014
Kyu-Won Jung, MS1,2, Young-Joo Won, PhD1,2, Hyun-Joo Kong, MS1,2, Chang-Mo Oh, MD, PhD1,2, Duk Hyoung Lee, MD, PhD2, Jin Soo Lee, MD, PhD1
Cancer Research and Treatment : Official Journal of Korean Cancer Association 2014;46(2):124-130.
DOI: https://doi.org/10.4143/crt.2014.46.2.124
Published online: April 15, 2014

1The Korea Central Cancer Registry, National Cancer Center, Goyang, Korea.

2National Cancer Control Institute, National Cancer Center, Goyang, Korea.

Correspondence: Young-Joo Won, PhD. The Korea Central Cancer Registry, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang 410-769, Korea.
Tel: 82-31-920-2015, Fax: 82-31-920-2179, astra67@ncc.re.kr
• Received: March 9, 2014   • Accepted: April 3, 2014

Copyright © 2014 by the Korean Cancer Association

This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 16,320 Views
  • 102 Download
  • 75 Web of Science
  • 69 Crossref
  • 80 Scopus
prev next
Full Article

Download PDF Download PDF

  • Purpose
    We studied and reported on cancer incidence and mortality rates as projected for the year 2014 in order to estimate Korea's current cancer burden.
  • Materials and Methods
    Cancer incidence data from 1999 to 2011 were obtained from the Korea National Cancer Incidence Database, and cancer mortality data from 1993 to 2012 were acquired from Statistics Korea. Cancer incidence in 2014 was projected by fitting a linear regression model to observed age-specific cancer incidence rates against observed years, then multiplying the projected age-specific rates by the age-specific population. For cancer mortality, a similar procedure was employed, except that a Joinpoint regression model was used to determine at which year the linear trend changed significantly.
  • Results
    A total of 265,813 new cancer cases and 74,981 cancer deaths are expected to occur in Korea in 2014. Further, the crude incidence rate per 100,000 of all sites combined will likely reach 524.7 and the age-standardized incidence rate, 338.5. Meanwhile, the crude mortality rate of all sites combined and age-standardized rate are projected to be 148.0 and 84.6, respectively. Given the rapid rise in prostate cancer cases, it is anticipated to be the fourth most frequently occurring cancer site in men for the first time.
  • Conclusion
    Cancer has become the most prominent public health concern in Korea, and as the population ages, the nation's cancer burden will continue to increase.
  • Key words: Incidence, Mortality, Neoplasms, Forecasting, Korea, 2014
As the leading cause of death in Korea [1], cancer has been the country's major public health concern since 1983. Over 200,000 patients were newly diagnosed with cancer in Korea, and one in four deaths is due to cancer [2]. To plan and implement comprehensive cancer control programs, it is important to estimate, in advance, the number of new cancer cases and deaths that could occur over the following year. Although the cancer registration system in Korea is very efficient and can provide nationwide cancer statistics within a relatively short time, a lag time of at least 2 years is required to collect, compile, and analyze the data on a specific year. In this study, however, we drew on relevant national data from the 1990s through 2012 to forecast the country's cancer incidence and mortality rates for the year 2014 in advance.
The Korean Ministry of Health and Welfare initiated a nationwide, hospital-based cancer registry, the Korea Central Cancer Registry (KCCR), in 1980. The history, objectives, and activities of the KCCR have been documented in detail elsewhere [3]. Incidence data from 1999 to 2011 were obtained for analyses from the Korea National Cancer Incidence Database (KNCI DB). Cancer cases were classified according to the International Classification of Diseases for Oncology, 3rd edition [4], and converted according to the International Classification of Diseases, 10th edition (ICD-10) [5]. Mortality data from 1993 to 2012 were acquired from Statistics Korea [1]. The cause of death was coded and classified according to ICD-10 [5].
The cancer sites included in this study were 1) all cancers combined and 2) the 24 common cancers: lip, oral cavity, and pharynx (C00-C14), esophagus (C15), stomach (C16), colon and rectum (C18-C20), liver and intrahepatic bile duct (liver) (C22), gallbladder and other parts of the biliary tract (gallbladder) (C23-C24), pancreas (C25), larynx (C32), lung and bronchus (lung) (C33-C34), breast (C50), cervix uteri (C53), corpus uteri (C54), ovary (C56), prostate (C61), testis (C62), kidney (C64), bladder (C67), brain and central nervous system (C70-C72), thyroid (C73), Hodgkin lymphoma (C81), non-Hodgkin lymphoma (C82-C85, C96), multiple myeloma (C90), leukemia (C91-C95), and others.
Population data for 1993-2013 were obtained from the resident registration population, reported by Statistics Korea. Data on the mid-year population, as of July 1 of the respective year, were analyzed. For the year 2014, however, we used population data as of December 31, 2013, because mid-2014 resident registration population data were not yet available at the time of analysis.
Due to the time required for data collection, compilation, quality control, and analysis, incidence and mortality data for a specific year are usually available 2-3 years later. Therefore, we attempted to project, ahead of 2014, the expected number of new cancer cases and deaths in Korea for the year so as to provide an estimate of the nation's current cancer burden. Linear regression models [6] were used to assess time trends and projections. Based on observed cancer incidence data, a linear regression model was fitted to age-specific rates by 5-year age groups against observed years. The estimated number of new cancer cases was calculated from the projected age-specific rates for 2014, by multiplying the rates by the projected 2014 age-specific population size. For thyroid and prostate cancer, which showed significant curvilinear trends, we used a square-root transformation when fitting a linear regression model and converted the predicted values back to the original scale.
To predict the cancer mortality rate in 2014, we first performed a Joinpoint regression analysis on the data available for 1993-2012 to detect the year when significant changes occurred in cancer mortality trends according to sex and cancer site. A Joinpoint regression describes changes in data trends by connecting several different line segments on a log scale at "joinpoint." This analysis was performed using the Joinpoint software (ver. 4.0; http://surveillance.cancer.gov/joinpoint) from the Surveillance Research Program of the US National Cancer Institute [7].
After identifying the year during which significant trend changes occurred through Joinpoint regression analysis, a simple linear regression model was fitted to the last line segment to estimate age-specific cancer mortality rates in 2014. Similar to the method used for the projection of cancer incidence, the number of new deaths in 2014 was then forecasted by multiplying age-specific cancer mortality rates by the corresponding year's age-specific population.
We summarized the results by using crude rates (CRs) and age-standardized rates (ASRs) of cancer incidence and mortality. ASRs were standardized using the world standard population [8] and expressed per 100,000 persons.
1. Incidence
A total of 265,813 new cancer cases are anticipated in 2014 (Table 1, Fig. 1), with slightly more female (n=134,358) than male (n=131,455) cancer patients expected in the coming year.
The CRs per 100,000 of all sites combined in 2014 are projected to be 519.0 and 530.4 in men and women, respectively. Meanwhile, projected ASRs per 100,000 of all sites combined are 358.4 and 338.3, respectively (Table 2). In men, the five leading primary sites of cancer are expected to be the stomach (CR, 92.7; ASR, 62.7), colon and rectum (CR, 88.1; ASR, 60.1), lung (CR, 67.7; ASR, 45.6), prostate (CR, 53.9; ASR, 36.9), and liver (CR, 50.0; ASR, 33.6), accounting for 67.9% of all newly diagnosed cancers in 2014. Prostate cancer is projected to be the fourth most common cancer site in men for the first time. In women, the five leading primary sites are expected to be the thyroid (CR, 195.8; ASR, 138.3), breast (CR, 72.6; ASR, 48.5), colon and rectum (CR, 54.6; ASR, 30.5), stomach (CR, 43.5; ASR, 24.8), and lung (CR, 29.8; ASR, 15.6), accounting for 74.7% of all newly diagnosed cancers (Fig. 1). Thyroid cancer alone is projected to account for approximately 36.9% (49,604 cases) of incident cases in women in 2014.
The five most common cancer sites expected in 2014 by sex and age group are shown in Table 3. Leukemia and thyroid cancer are expected to be the most common forms of cancer in both genders for the 0-14 and 15-34 age groups. Stomach cancer is predicted to be the most prevalent in men aged 35-64 years, while lung cancer is expected to be more frequent in men aged 65 and over. Thyroid cancer is predicted to be the most common cancer in women 35-64 years of age, whereas colorectal cancer is expected to be the most prevalent in women aged 65 and over. These projections indicate that the incidences of stomach, lung, liver, colorectal and prostate cancers will increase gradually with age. In women, the age-specific incidence rates of colorectal, liver, lung and cervical cancers denote a rising trend in these cancers with age; however, the incidence of breast and thyroid cancer in women is expected to level off after the late 40s and early 50s, respectively (Fig. 2).
2. Mortality
It is estimated that 74,981 cancer deaths will occur in Korea during 2014 (Table 1, Fig. 1). The CRs per 100,000 of all sites combined in 2014 for men and women are projected to be 184.2 and 111.8, respectively, while the ASRs per 100,000 of all sites combined are expected to be 125.7 and 55.3, respectively (Table 4). The five leading cancer sites causing mortality in men are predicted to be lung (CR, 48.7; ASR, 32.7), liver (CR, 31.7; ASR, 21.4), stomach (CR, 20.0; ASR, 13.6), colon and rectum (CR, 19.9; ASR, 13.7), and pancreas (CR, 10.7; ASR, 7.2). During the same time period, lung cancer (CR, 18.3; ASR, 8.5) is projected to be the leading cancer site in women, causing mortality, followed by colon and rectum (CR, 14.6; ASR, 6.7), stomach (CR, 11.1; ASR, 5.2), liver (CR, 10.8; ASR, 5.4), and pancreas (CR, 9.6; ASR, 4.5).
The predicted age-specific mortality rates of the selected cancers for males and females in 2014 are shown in further detail in Fig. 3. When examined by age, Korean men and women aged 60 and over are expected to have the highest mortality rates from lung cancer.
A total of 265,813 new cancer cases and 74,981 cancer deaths are expected to occur in Korea during 2014. In Korean males, stomach, colorectal, lung, prostate, and liver cancers are anticipated to be the most commonly occurring, while lung, liver, stomach, colorectal, and pancreatic cancers are expected to be the most common causes of cancer-related deaths. In Korean women, thyroid, breast, colorectal, stomach, and lung cancers are anticipated to be the most prevalent, while lung, colorectal, stomach, liver, and pancreatic cancers are projected to be the most common causes of cancer-related deaths.
Cancer is, at present, one of the foremost public health concerns in Korea. The country will likely see its cancer burden continue to grow with the aging of its population. The current projections on cancer incidence and mortality for 2014 represent an important resource for planning and evaluating cancer-control programs. As the estimates in this study are model-based, there is a need to exercise caution when using them.
Acknowledgements
This work was supported by a research grant from the National Cancer Center (No. 1310220), Republic of Korea.

Conflict of interest relevant to this article was not reported.

  • 1. Statistics Korea [Internet]. Daejeon: Statistics Korea; 2014. cited 2014 Jan 24Available from: http://kosis.kr
  • 2. Jung KW, Won YJ, Kong HJ, Oh CM, Seo HG, Lee JS. Cancer statistics in Korea: incidence, mortality, survival and prevalence in 2010. Cancer Res Treat. 2013;45:1–14. PMID: 23613665ArticlePubMedPMCPDF
  • 3. Shin HR, Won YJ, Jung KW, Kong HJ, Yim SH, Lee JK, et al. Nationwide cancer incidence in Korea, 1999~2001: first result using the National Cancer Incidence Database. Cancer Res Treat. 2005;37:325–331. PMID: 19956367ArticlePubMedPMCPDF
  • 4. Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, et al. International classification of diseases for oncology. 3rd ed. Geneva: World Health Organization; 2000.
  • 5. World Health OrganizationInternational statistical classification of diseases and related health problems. 10th rev. Geneva: World Health Organization; 1994.
  • 6. Boyle P, Parkin DM. Statistical methods for registries. In: Jensen OM, Parkin DM, MacLennan R, Muir CS, Skeet RG, editors. Cancer registration: principles and methods. IARC Scientific Publication No. 95. Lyon: IARC Press; 1991. p. 126–158.
  • 7. National Cancer InstituteJoinpoint regression program, version 4.0 [Internet]. Bethesda: National Cancer Institute; 2014. cited 2014 Jan 8Available from: http://surveillance.cancer.gov/joinpoint/
  • 8. Segi M. Cancer mortality for selected sites in 24 countries (1950-1957). Sendai: Tohoku University School of Medicine; 1960.
Fig. 1
The 10 leading types of estimated new cancer cases and deaths by sex in 2014. (A) Estimated new cases. (B) Estimated deaths.
crt-46-124-g001.jpg
Fig. 2
Projected age-specific incidences of major cancers during 2014 in Korea. (A) Male. (B) Female.
crt-46-124-g002.jpg
Fig. 3
Projected age-specific mortality rates of major cancers during 2014 in Korea. (A) Male. (B) Female.
crt-46-124-g003.jpg
Table 1
Estimated new cancer cases and deaths by sex during 2014 in Korea
Site Estimated new cases Estimated deaths
Both Male Female Both Male Female
All sites 265,813 131,455 134,358 74,981 46,653 28,328
Lip, oral cavity, and pharynx 3,059 2,254 805 1,037 763 274
Esophagus 2,313 2,125 188 1,215 1,135 80
Stomach 34,478 23,471 11,007 7,876 5,056 2,820
Colon and rectum 36,125 22,304 13,821 8,746 5,048 3,698
Liver 17,182 12,654 4,528 10,761 8,017 2,744
Gallbladdera) 5,841 2,918 2,923 3,962 1,912 2,050
Pancreas 5,935 3,185 2,750 5,133 2,697 2,436
Larynx 1,063 1,029 34 374 367 7
Lung 24,697 17,139 7,558 16,990 12,346 4,644
Breast 18,456 74 18,382 2,162 17 2,145
Cervix uteri 3,205 - 3,205 784 - 784
Corpus uteri 2,319 - 2,319 277 - 277
Ovary 2,271 - 2,271 1,020 - 1,020
Prostate 13,650 13,650 - 1,706 1,706 -
Testis 233 233 - 19 19 -
Kidney 4,904 3,376 1,528 978 671 307
Bladder 4,173 3,358 815 1,264 945 319
Brain and CNS 1,867 995 872 1,118 593 525
Thyroid 59,516 9,912 49,604 373 114 259
Hodgkin lymphoma 283 182 101 54 36 18
Non-Hodgkin lymphoma 5,021 2,748 2,273 1,584 917 667
Multiple myeloma 1,368 733 635 876 476 400
Leukemia 3,063 1,721 1,342 1,737 999 738
Other and ill-defined 14,791 7,394 7,397 4,935 2,819 2,116

CNS, central nervous system.

a) Includes the gallbladder and other/unspecified parts of the biliary tract.

Table 2
Estimated crude and age-standardized cancer incidences by sex during 2014 in Korea
Site Crude incidence rate per 100,000 Age-standardized incidence rate per 100,000a)
Both Male Female Both Male Female
All sites 524.7 519.0 530.4 338.5 358.4 338.3
Lip, oral cavity, and pharynx 6.0 8.9 3.2 4.0 6.1 2.1
Esophagus 4.6 8.4 0.7 2.8 5.7 0.4
Stomach 68.1 92.7 43.5 42.1 62.7 24.8
Colon and rectum 71.3 88.1 54.6 44.1 60.1 30.5
Liver 33.9 50.0 17.9 21.0 33.6 9.8
Gallbladderb) 11.5 11.5 11.5 6.6 7.9 5.6
Pancreas 11.7 12.6 10.9 6.8 8.5 5.4
Larynx 2.1 4.1 0.1 1.3 2.7 0.1
Lung 48.8 67.7 29.8 28.4 45.6 15.6
Breast 36.4 0.3 72.6 24.4 0.2 48.5
Cervix uteri 6.3 - 12.7 4.2 - 8.2
Corpus uteri 4.6 - 9.2 3.0 - 6.0
Ovary 4.5 - 9.0 3.1 - 6.1
Prostate 26.9 53.9 - 16.2 36.9 -
Testis 0.5 0.9 - 0.5 0.9 -
Kidney 9.7 13.3 6.0 6.4 9.2 3.8
Bladder 8.2 13.3 3.2 4.7 8.9 1.5
Brain and CNS 3.7 3.9 3.4 3.0 3.4 2.7
Thyroid 117.5 39.1 195.8 82.6 27.6 138.3
Hodgkin lymphoma 0.6 0.7 0.4 0.5 0.6 0.4
Non-Hodgkin lymphoma 9.9 10.9 9.0 6.9 8.1 5.9
Multiple myeloma 2.7 2.9 2.5 1.6 2.0 1.4
Leukemia 6.1 6.8 5.3 5.3 6.2 4.5
Other and ill-defined 29.2 29.2 29.2 19.0 21.4 17.1

CNS, central nervous system.

a) Age adjusted to the world standard population,

b) Includes the gallbladder and other/unspecified parts of the biliary tract.

Table 3
Estimated cancer incidence by age group and sex during 2014 in Korea
Rank Age group (yr)
0-14 15-34 35-64 ≥65
Male
 1 Leukemia Thyroid Stomach Lung
  (5.2) (17.1) (102.6) (475.1)
 2 Brain and CNS Colon and rectum Colon and rectum Stomach
  (2.4) (3.4) (96.2) (444.1)
 3 Non-Hodgkin lymphoma Leukemia Thyroid Colon and rectum
  (2.2) (3.3) (66.3) (425.0)
 4 Kidney Non-Hodgkin lymphoma Liver Prostate
  (0.6) (3.2) (63.6) (399.4)
 5 Liver/Testis Stomach Lung Liver
(0.3) (2.4) (42.4) (201.5)
Female
 1 Leukemia Thyroid Thyroid Colon and rectum
  (4.3) (89.4) (343.4) (210.9)
 2 Brain and CNS Breast Breast Stomach
  (2.0) (11.9) (131.9) (156.9)
 3 Non-Hodgkin lymphoma Cervix uteri Colon and rectum Lung
  (1.2) (5.4) (52.8) (135.2)
 4 Ovary Stomach Stomach Thyroid
  (0.8) (4.0) (44.5) (120.5)
 5 Thyroid Ovary Lung Liver
  (0.7) (2.9) (23.1) (78.9)

CNS, central nervous system.

Table 4
Estimated crude and age-standardized cancer mortality rates by sex during 2014 in Korea
Site/Type Crude mortality rate per 100,000 Age-standardized mortality rate per 100,000a)
Both Male Female Both Male Female
All sites 148.0 184.2 111.8 84.6 125.7 55.3
Lip, oral cavity, and pharynx 2.1 3.0 1.1 1.2 2.0 0.6
Esophagus 2.4 4.5 0.3 1.4 3.0 0.1
Stomach 15.6 20.0 11.1 8.7 13.6 5.2
Colon and rectum 17.3 19.9 14.6 9.7 13.7 6.7
Liver 21.2 31.7 10.8 12.7 21.4 5.4
Gallbladderb) 7.8 7.6 8.1 4.2 5.2 3.6
Pancreas 10.1 10.7 9.6 5.7 7.2 4.5
Larynx 0.7 1.5 0.0 0.4 1.0 0.0
Lung 33.5 48.7 18.3 18.6 32.7 8.5
Breast 4.3 0.1 8.5 2.7 0.1 5.2
Cervix uteri 1.6 - 3.1 0.9 - 1.7
Corpus uteri 0.6 - 1.1 0.3 - 0.6
Ovary 2.0 - 4.0 1.2 - 2.3
Prostate 3.4 6.7 - 1.7 4.8 -
Testis 0.0 0.1 - 0.0 0.1 -
Kidney 1.9 2.7 1.2 1.1 1.8 0.6
Bladder 2.5 3.7 1.3 1.3 2.6 0.5
Brain and CNS 2.2 2.3 2.1 1.6 1.8 1.3
Thyroid 0.7 0.5 1.0 0.4 0.3 0.4
Hodgkin lymphoma 0.1 0.1 0.1 0.1 0.1 0.0
Non-Hodgkin lymphoma 3.1 3.6 2.6 1.8 2.5 1.3
Multiple myeloma 1.7 1.9 1.6 1.0 1.3 0.8
Leukemia 3.4 3.9 2.9 2.3 2.9 1.8
Other and ill-defined 9.7 11.1 8.4 5.6 7.7 4.1

CNS, central nervous system.

a) Age adjusted to the world standard population,

b) Includes the gallbladder and other/unspecified parts of the biliary tract.

Figure & Data

REFERENCES

    Citations

    Citations to this article as recorded by  
    • Updates on global epidemiology, risk and prognostic factors of gastric cancer
      Wen-Juan Yang, He-Ping Zhao, Yan Yu, Ji-Han Wang, Lei Guo, Jun-Ye Liu, Jie Pu, Jing Lv
      World Journal of Gastroenterology.2023; 29(16): 2452.     CrossRef
    • Excellent Outcomes in Children, Adolescents, and Young Adults with Ovarian Germ Cell Tumors Treated by Either Reduced- or Standard-Dose Bleomycin
      Meerim Park, Jin Kyung Suh, Jun Ah Lee, Hyeon Jin Park, Eun Young Park, Chong Woo Yoo, Myong Cheol Lim, Sang-Yoon Park, Byung Kiu Park
      Cancers.2023; 15(21): 5290.     CrossRef
    • Analysis of postoperative pulmonary complications after gastrectomy for gastric cancer: development and validation of a nomogram
      Ling Zhou, Yuanna Li, Yuanbo Ni, Cunming Liu
      Frontiers in Surgery.2023;[Epub]     CrossRef
    • Glycosidic flavonoids and their potential applications in cancer research: a review
      Abuyaseer Abusaliya, Sang Eun Ha, Pritam Bhagwan Bhosale, Hun Hwan Kim, Min Yeong Park, Preethi Vetrivel, Gon Sup Kim
      Molecular & Cellular Toxicology.2022; 18(1): 9.     CrossRef
    • Nueva clasificación molecular del carcinoma de endometrio: impacto en el diagnóstico histopatológico, tratamiento y pronóstico
      Camilo Andrés Pérez-Montiel
      MedUNAB.2022; 24(3): 365.     CrossRef
    • Clinical outcomes of targeted therapies in elderly patients aged ≥ 80 years with metastatic colorectal cancer
      Hee Ryeong Jang, Hui-Young Lee, Seo-Young Song, Kyu-Hyoung Lim
      World Journal of Clinical Cases.2022; 10(28): 10066.     CrossRef
    • The utility of high-mobility group A2 overexpression for predicting the prognosis of gastric cancer patients and its contribution to poor prognosis via chemoresistance and the propensity for the occurrence of carcinomatosis peritonei
      Hayemin Lee, Han Hong Lee, Chae Youn Lim, Junhyun Lee
      Surgery.2021; 169(5): 1213.     CrossRef
    • Immunotherapeutic advances in gastric cancer
      Akira Yoneda, Tamotsu Kuroki, Susumu Eguchi
      Surgery Today.2021; 51(11): 1727.     CrossRef
    • Apoptotic Effects of Anthocyanins from Vitis coignetiae Pulliat Are Enhanced by Augmented Enhancer of the Rudimentary Homolog (ERH) in Human Gastric Carcinoma MKN28 Cells
      Cheol Park, Won Sup Lee, Se-Il Go, Sang-Ho Jeong, Jiyun Yoo, Hee-Jae Cha, Young-Joon Lee, Heui-Soo Kim, Sun-Hee Leem, Hye Jung Kim, Gon Sup Kim, Soon-Chan Hong, Yung Hyun Choi
      International Journal of Molecular Sciences.2021; 22(6): 3030.     CrossRef
    • The effect of marital and insurance status on the survival of elderly patients with stage M1b colon cancer: a SEER-based study
      Chenghui Zhou, Yiwei Zhang, Xi Hu, Min Fang, Shuai Xiao
      BMC Cancer.2021;[Epub]     CrossRef
    • Ameliorating and anti-inflammatory role of Balanites aegyptiaca aqueous extract on Doxorubicin-induced hepatotoxicity in male Wistar rats
      Hanaa F.A. Elkareem, Abd El-Naby I. Essawy, Mahmoud Ashry, Manal A. Badawi, Khaled G. Abdel-Wahhab
      Egyptian Pharmaceutical Journal.2021; 20(2): 157.     CrossRef
    • Long non-coding RNA HOXA-AS3 facilitates the malignancy in colorectal cancer by miR-4319/SPNS2 axis
      Yang Jiang, Xiao-yu Yu, Hui-xin Sun, Xin-yue Gu, Jing-shu Geng
      Journal of Physiology and Biochemistry.2021; 77(4): 653.     CrossRef
    • A Simple Predictive Index of the Abdominal Shape for Postoperative Complications After Laparoscopy-Assisted Distal Gastrectomy for Gastric Cancer
      Wei Tao, Yu-Xi Cheng, Xiao-Yu Liu, Bin Zhang, Chao Yuan, Dong Peng, Wei Zhang
      Frontiers in Surgery.2021;[Epub]     CrossRef
    • Negative Impact of Endoscopic Submucosal Dissection on Short-Term Surgical Outcomes of Subsequent Laparoscopic Distal Gastrectomy for Gastric Cancer
      Hayemin Lee, Han Hong Lee, Kyo Young Song, Cho Hyun Park, Junhyun Lee
      Annals of Surgical Oncology.2020; 27(1): 313.     CrossRef
    • Napabucasin overcomes cisplatin resistance in ovarian germ cell tumor-derived cell line by inhibiting cancer stemness
      Silvia Schmidtova, Lambert C. J. Dorssers, Katarina Kalavska, Ad J. M. Gillis, J. Wolter Oosterhuis, Hans Stoop, Svetlana Miklikova, Zuzana Kozovska, Monika Burikova, Katarina Gercakova, Erika Durinikova, Michal Chovanec, Michal Mego, Lucia Kucerova, Leen
      Cancer Cell International.2020;[Epub]     CrossRef
    • Role of Human Epididymis Protein 4 (HE4) in Determining Survival of Patients With Endometrial Cancer: A Meta-Analysis
      Ying He, Jing Wang, Chun-Xing Ma, Yan-Hua Kang
      Technology in Cancer Research & Treatment.2020;[Epub]     CrossRef
    • Effect of intraoperative lung-protective mechanical ventilation on pulmonary oxygenation function and postoperative pulmonary complications after laparoscopic radical gastrectomy
      Jing Liu, Zhipeng Meng, Ran lv, Yaping Zhang, Gaojian Wang, Junran Xie
      Brazilian Journal of Medical and Biological Research.2019;[Epub]     CrossRef
    • EGFR Exon 19 Deletion is Associated With Favorable Overall Survival After First-line Gefitinib Therapy in Advanced Non–Small Cell Lung Cancer Patients
      Yong Won Choi, So Yeon Jeon, Geum Sook Jeong, Hyun Woo Lee, Seong Hyun Jeong, Seok Yun Kang, Joon Seong Park, Jin-Hyuk Choi, Young Wha Koh, Jae Ho Han, Seung Soo Sheen
      American Journal of Clinical Oncology.2018; 41(4): 385.     CrossRef
    • Early Detection is Important to Reduce the Economic Burden of Gastric Cancer
      Jie-Hyun Kim, Sung Soo Kim, Jeong Hoon Lee, Da Hyun Jung, Dae Young Cheung, Woo-Chul Chung, Soo-Heon Park
      Journal of Gastric Cancer.2018; 18(1): 82.     CrossRef
    • Safety of Laparoscopic Radical Gastrectomy in Gastric Cancer Patients with End-Stage Renal Disease
      Hayemin Lee, Cho Hyun Park, Seung Man Park, Wook Kim, Hyung Min Chin, Jin Jo Kim, Kyo Young Song, Sung Geun Kim, Kyong Hwa Jun, Jeong Goo Kim, Han Hong Lee, Junhyun Lee, Dong Jin Kim
      Journal of Gastric Cancer.2018; 18(3): 287.     CrossRef
    • Prediction of Recurrence by Preoperative Intratumoral FDG Uptake Heterogeneity in Endometrioid Endometrial Cancer
      Seo Young Kang, Gi Jeong Cheon, Maria Lee, Hee Seung Kim, Jae-Weon Kim, Noh-Hyun Park, Yong Sang Song, Hyun Hoon Chung
      Translational Oncology.2017; 10(2): 178.     CrossRef
    • Evaluation of Robust Classifier Algorithm for Tissue Classification under Various Noise Levels
      Su Hyun Youn, Ki Young Shin, Ahnryul Choi, Joung Hwan Mun
      ETRI Journal.2017; 39(1): 87.     CrossRef
    • Safety of laparoscopic radical gastrectomy in gastric cancer patients with liver cirrhosis
      Dong Jin Kim, Cho Hyun Park, Wook Kim, Hyung Min Jin, Jin Jo Kim, Han Hong Lee, Jun Hyun Lee
      Surgical Endoscopy.2017; 31(10): 3898.     CrossRef
    • Burden of Disease Attributable to Smoking in Korea
      Aqeela Zahra, Hae-Kwan Cheong, Jae-Hyun Park
      Asia Pacific Journal of Public Health.2017; 29(1): 47.     CrossRef
    • Does the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor differ according to the type of EGFR mutation in non-small cell lung cancer?
      Yong Won Choi, Jin-Hyuk Choi
      The Korean Journal of Internal Medicine.2017; 32(3): 422.     CrossRef
    • Single-incision endoscopic thyroidectomy for papillary thyroid cancer: A pilot study
      Jinbeom Cho, Yohan Park, Jongmin Baek, Kiyoung Sung
      International Journal of Surgery.2017; 43: 1.     CrossRef
    • Immunotherapy in Gastrointestinal Cancers
      Letizia Procaccio, Marta Schirripa, Matteo Fassan, Loredana Vecchione, Francesca Bergamo, Alessandra Anna Prete, Rossana Intini, Chiara Manai, Vincenzo Dadduzio, Alice Boscolo, Vittorina Zagonel, Sara Lonardi
      BioMed Research International.2017; 2017: 1.     CrossRef
    • Optimization of RNA Extraction from Formalin-Fixed Paraffin-Embedded Blocks for Targeted Next-Generation Sequencing
      Yoojin Choi, Aeree Kim, Jinkyoung Kim, Jinhwan Lee, Soo Yeon Lee, Chungyeul Kim
      Journal of Breast Cancer.2017; 20(4): 393.     CrossRef
    • Morusin induces apoptosis by regulating expression of Bax and Survivin in human breast cancer cells
      Sukmin Kang, Eun-Ok Kim, Sung-Hoon Kim, Jun-Hee Lee, Kwang Seok Ahn, Miyong Yun, Seok-Geun Lee
      Oncology Letters.2017; 13(6): 4558.     CrossRef
    • Is the Location of the Tumor Another Prognostic Factor for Patients With Colon Cancer?
      Myung-Kyu Jung, Ui Sup Shin, Young-Jun Ki, Yong-Bae Kim, Sun-Mi Moon, Se-Jin Sung
      Annals of Coloproctology.2017; 33(6): 210.     CrossRef
    • Stromal p16 expression is significantly increased in endometrial carcinoma
      Gun Yoon, Chang Won Koh, Nara Yoon, Ji-Ye Kim, Hyun-Soo Kim
      Oncotarget.2017; 8(3): 4826.     CrossRef
    • Postoperative Lower Extremity Edema in Patients with Primary Endometrial Cancer
      Hyo Sook Bae, Myong Cheol Lim, Jeong Seon Lee, Yumi Lee, Byung Ho Nam, Sang-Soo Seo, Sokbom Kang, Seung Hyun Chung, Joo-Young Kim, Sang-Yoon Park
      Annals of Surgical Oncology.2016; 23(1): 186.     CrossRef
    • Comparison of Lower Extremity Edema in Locally Advanced Cervical Cancer: Pretreatment Laparoscopic Surgical Staging with Tailored Radiotherapy Versus Primary Radiotherapy
      Se Ik Kim, Myong Cheol Lim, Jeong Seon Lee, Yeon-Joo Kim, Sang-Soo Seo, Sokbom Kang, Chong Woo Yoo, Byung-Ho Nam, Joo-Young Kim, Seung Hyun Chung, Sang-Yoon Park
      Annals of Surgical Oncology.2016; 23(1): 203.     CrossRef
    • Tolerability and Outcomes of First-Line Pemetrexed-Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in Korean Patients with Advanced Nonsquamous Non-small Cell Lung Cancer: A Post Hoc Descriptive Subgroup Analysis of
      Jin Hyoung Kang, Myung-Ju Ahn, Dong-Wan Kim, Eun Kyung Cho, Joo-Hang Kim, Sang Won Shin, Xin Wang, Jong Seok Kim, Mauro Orlando, Keunchil Park
      Cancer Research and Treatment.2016; 48(2): 458.     CrossRef
    • Anti-cancer effects of traditional Korean wild vegetables in complementary and alternative medicine
      Hyun-Mok Ju, Kwang-Won Yu, Sung-Dae Cho, Sun Hee Cheong, Ki Han Kwon
      Complementary Therapies in Medicine.2016; 24: 47.     CrossRef
    • Preoperative Prediction of Cardiophrenic Lymph Node Metastasis in Advanced Ovarian Cancer Using Computed Tomography
      Tae-Hyung Kim, Myong Cheol Lim, Se Ik Kim, Sang-Soo Seo, Sun Ho Kim, Sang-Yoon Park
      Annals of Surgical Oncology.2016; 23(4): 1302.     CrossRef
    • Changes in Noninvasive Liver Fibrosis Indices and Spleen Size During Chemotherapy
      Sehhoon Park, Hwi Young Kim, Haeryoung Kim, Jin Hyun Park, Jung Ho Kim, Ki Hwan Kim, Won Kim, In Sil Choi, Yong Jin Jung, Jin-Soo Kim
      Medicine.2016; 95(2): e2454.     CrossRef
    • CompoundEGFRmutation is frequently detected with co-mutations of actionable genes and associated with poor clinical outcome in lung adenocarcinoma
      Eun Young Kim, Eun Na Cho, Heae Surng Park, Ji Young Hong, Seri Lim, Jong Pil Youn, Seung Yong Hwang, Yoon Soo Chang
      Cancer Biology & Therapy.2016; 17(3): 237.     CrossRef
    • Outcomes of fertility-sparing surgery among young women with FIGO stage I clear cell carcinoma of the ovary
      Jeong-Yeol Park, Dae-Shik Suh, Jong-Hyeok Kim, Yong-Man Kim, Young-Tak Kim, Joo-Hyun Nam
      International Journal of Gynecology & Obstetrics.2016; 134(1): 49.     CrossRef
    • Risk Factors for Gallstone Formation in Resected Gastric Cancer Patients
      Kyu-hyun Paik, Jong-Chan Lee, Hyoung Woo Kim, Jingu Kang, Yoon Suk Lee, Jin-Hyeok Hwang, Sang Hoon Ahn, Do Joong Park, Hyung-Ho Kim, Jaihwan Kim
      Medicine.2016; 95(15): e3157.     CrossRef
    • Polyphenols fromArtemisia annuaL Inhibit Adhesion and EMT of Highly Metastatic Breast Cancer Cells MDA-MB-231
      Young Shin Ko, Won Sup Lee, Radha Panchanathan, Young Nak Joo, Yung Hyun Choi, Gon Sup Kim, Jin-Myung Jung, Chung Ho Ryu, Sung Chul Shin, Hye Jung Kim
      Phytotherapy Research.2016; 30(7): 1180.     CrossRef
    • Prognostic Factors for Recurrence and Progression in Korean Non-Muscle-Invasive Bladder Cancer Patients: A Retrospective, Multi-Institutional Study
      Hyung Suk Kim, Ja Hyeon Ku, Se Joong Kim, Sung Joon Hong, Sung Hoo Hong, Hong Sup Kim, Tae Gyun Kwon, Jin Seon Cho, Seong Soo Jeon, Kwan Joong Joo, Han Jong Ahn, Hong Seok Park, Do Hwan Seong, Dong Deuk Kwon, Hyung Jin Kim, Jae Sung Lim, Hyung-Lae Lee
      Yonsei Medical Journal.2016; 57(4): 855.     CrossRef
    • Tumore del colon retto: percorsi diagnostici sulla base di linee guida internazionali
      Maria Golato, Marco Moretti, Stefano Martinotti, Elena Maria Toniato, Massimiliano Bonafè, Beatrice Caruso, Marika Caruso, Marzia Cozzi, Vincenzo De Iuliis, Romolo Marco Dorizzi, Mario Laneve, Franca Maria Lattanzio, Myriam Luongo, Maria Grazia Marin, Sab
      La Rivista Italiana della Medicina di Laboratorio - Italian Journal of Laboratory Medicine.2016; 12(2): 70.     CrossRef
    • Endometrial cancer: Not your grandmother's cancer
      Jessica N. McAlpine, Sarah M. Temkin, Helen J. Mackay
      Cancer.2016; 122(18): 2787.     CrossRef
    • Knowledge of HPV and Surgery among Women Who Underwent Cervical Conization: A Korean Multi-Center Study
      So Yeun Jun, Se Ik Kim, Myong Cheol Lim, Jung-Yun Lee, San Hui Lee, Yong Jung Song, Kyoung-Chul Chun, Jae Weon Kim, Sang-Yoon Park
      Yonsei Medical Journal.2016; 57(5): 1222.     CrossRef
    • Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: Earlier prognostic information to guide treatment
      Aline Talhouk, Lien N. Hoang, Melissa K. McConechy, Quentin Nakonechny, Joyce Leo, Angela Cheng, Samuel Leung, Winnie Yang, Amy Lum, Martin Köbel, Cheng-Han Lee, Robert A. Soslow, David G. Huntsman, C. Blake Gilks, Jessica N. McAlpine
      Gynecologic Oncology.2016; 143(1): 46.     CrossRef
    • Cause of Death in Korean Men with Prostate Cancer: an Analysis of Time Trends in a Nationwide Cohort
      Jinsung Park, Beomseok Suh, Dong Wook Shin, Jun Hyuk Hong, Hanjong Ahn
      Journal of Korean Medical Science.2016; 31(11): 1802.     CrossRef
    • Use of a Comprehensive Geriatric Assessment to Predict Short-Term Postoperative Outcome in Elderly Patients With Colorectal Cancer
      Yoon Hyun Lee, Heung-Kwon Oh, Duck-Woo Kim, Myong Hoon Ihn, Jee Hyun Kim, Il Tae Son, Sung Il Kang, Gwang Il Kim, Soyeon Ahn, Sung-Bum Kang
      Annals of Coloproctology.2016; 32(5): 161.     CrossRef
    • New classification of endometrial cancers: the development and potential applications of genomic-based classification in research and clinical care
      A. Talhouk, J. N. McAlpine
      Gynecologic Oncology Research and Practice.2016;[Epub]     CrossRef
    • Polyphenols from Korean prostrate spurge Euphorbia supina induce apoptosis through the Fas-associated extrinsic pathway and activation of ERK in human leukemic U937 cells
      MIN-HO HAN, WON SUP LEE, ARULKUMAR NAGAPPAN, HYE JUNG KIM, CHEOL PARK, GI-YOUNG KIM, SANG HOON HONG, NAM DEUK KIM, GONSUP KIM, CHUNG HO RYU, SUNG CHUL SHIN, YUNG HYUN CHOI
      Oncology Reports.2016; 36(1): 99.     CrossRef
    • Is fourth-line chemotherapy routine practice in advanced non-small cell lung cancer?
      Yong Won Choi, Mi Sun Ahn, Geum Sook Jeong, Hyun Woo Lee, Seong Hyun Jeong, Seok Yun Kang, Joon Seong Park, Jin-Hyuk Choi, Soon Young Lee
      Lung Cancer.2015; 87(2): 155.     CrossRef
    • Prevalence of Precancerous Conditions and Gastric Cancer Based upon the National Cancer Screening Program in Korea for 7 Years, Single Center Experience
      Ji Hyuk Kang, Yun Jeong Lim, Jung Hyun Kang, Jae Nam Yang, Seung Min Shin, Jae Hyeuk Choi, Jin Ho Lee
      Gastroenterology Research and Practice.2015; 2015: 1.     CrossRef
    • A phase II study of capecitabine and oral leucovorin as a third-line chemotherapy in patients with metastatic colorectal cancer
      Dae Ro Choi, Sang Nam Yoon, Hyeong Su Kim, Jung Han Kim, Kwang Yong Kim, Byung Chun Kim, Young Kyun Choi, Jin Bae Kim, Boram Han, Hun Ho Song, Dae Young Zang
      Cancer Chemotherapy and Pharmacology.2015; 75(3): 639.     CrossRef
    • Survival outcome in endometrial cancer patients according to hereditary predisposition
      Heon Jong Yoo, Myong Cheol Lim, Yedong Son, Sang-Soo Seo, Sokbom Kang, Sun Ho Kim, Chong Woo Yoo, Sang-Yoon Park
      Taiwanese Journal of Obstetrics and Gynecology.2015; 54(1): 24.     CrossRef
    • Outcomes of pediatric and adolescent girls with malignant ovarian germ cell tumors
      Jeong-Yeol Park, Dae-Yeon Kim, Dae-Shik Suh, Jong-Hyeok Kim, Yong-Man Kim, Young-Tak Kim, Joo-Hyun Nam
      Gynecologic Oncology.2015; 137(3): 418.     CrossRef
    • Frequency and spectrum of actionable pathogenic secondary findings in 196 Korean exomes
      Mi-Ae Jang, Sang-Heon Lee, Namshin Kim, Chang-Seok Ki
      Genetics in Medicine.2015; 17(12): 1007.     CrossRef
    • Quality of life and sexuality comparison between sexually active ovarian cancer survivors and healthy women
      Se Ik Kim, Yumi Lee, Myong Cheol Lim, Jungnam Joo, KiByung Park, Dong Ock Lee, Sang-Yoon Park
      Journal of Gynecologic Oncology.2015; 26(2): 148.     CrossRef
    • Need to Pay More Attention to Attendance at Follow-Up Consultation after Cancer Screening in Smokers and Drinkers
      Jaeyong Shin, Eun-Cheol Park, Hong-Chul Bae, Seri Hong, Suk-Yong Jang, Jae-Hyun Kim, Jee Suk Chang, Sang Gyu Lee
      Asian Pacific Journal of Cancer Prevention.2015; 16(1): 109.     CrossRef
    • Histological variant as the significant predictor of survival in patients with lymph node positive urothelial carcinoma of the bladder
      Hyung Suk Kim, Kyung Chul Moon, Chang Wook Jeong, Cheol Kwak, Hyeon Hoe Kim, Ja Hyeon Ku
      Scientific Reports.2015;[Epub]     CrossRef
    • Association between Promoter Polymorphisms of TFF1, TFF2, and TFF3 and the Risk of Gastric and Diffuse Gastric Cancers in a Korean Population
      Eun-Heui Jin, Sang-Il Lee, JaeWoo Kim, Eun Young Seo, Su Yel Lee, Gang Min Hur, Sanghee Shin, Jang Hee Hong
      Journal of Korean Medical Science.2015; 30(8): 1035.     CrossRef
    • Trends in the Use of Chemotherapy before and after Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer in Korea
      Sung Han Kim, Ho Kyung Seo, Hee Chul Shin, Sung Ja Chang, Sooin Yun, Jungnam Joo, Ja Hyeon Ku, Hyung Suk Kim, Hwang Gyun Jeon, Byong Chang Jeong, In Gab Jeong, Seok Ho Kang, Bumsik Hong
      Journal of Korean Medical Science.2015; 30(8): 1150.     CrossRef
    • Assessment of Breast Cancer Patients' Knowledge and Decisional Conflict Regarding Tamoxifen Use
      Se Ik Kim, Yumi Lee, Yedong Son, So Yeun Jun, Sooin Yun, Hyo Sook Bae, Myong Cheol Lim, So-Youn Jung, Jungnam Joo, Eun Sook Lee
      Journal of Korean Medical Science.2015; 30(11): 1604.     CrossRef
    • Survival analysis for colon subsite and rectal cancers: Experience from a single surgeon
      Inhwa Lee, Seung-Hyun Baek, Hyunsung Kim, Hong-Jae Jo, Nahm-Gun Oh, Sanghwa Ko
      Korean Journal of Clinical Oncology.2015; 11(2): 114.     CrossRef
    • Definitive radiotherapy with concurrent oncothermia for stage IIIB non-small-cell lung cancer: A case report
      SEUNG-GU YEO
      Experimental and Therapeutic Medicine.2015; 10(2): 769.     CrossRef
    • Chemotherapy for colorectal cancer in the elderly
      Jung Han Kim
      World Journal of Gastroenterology.2015; 21(17): 5158.     CrossRef
    • Comparison of adenocarcinoma and adenosquamous carcinoma in patients with early-stage cervical cancer after radical surgery
      Min-Hyun Baek, Jeong-Yeol Park, Daeyeon Kim, Dae-Shik Suh, Jong-Hyeok Kim, Yong-Man Kim, Young-Tak Kim, Joo-Hyun Nam
      Gynecologic Oncology.2014; 135(3): 462.     CrossRef
    • Chemotherapy in Elderly Patients with Colorectal Cancer
      Hye Sook Han
      Korean Journal of Medicine.2014; 87(5): 530.     CrossRef
    • Diet and Cancer Risk in the Korean Population: A Meta-analysis
      Hae Dong Woo, Sohee Park, Kyungwon Oh, Hyun Ja Kim, Hae Rim Shin, Hyun Kyung Moon, Jeongseon Kim
      Asian Pacific Journal of Cancer Prevention.2014; 15(19): 8509.     CrossRef
    • Dietary Flavonoids and Gastric Cancer Risk in a Korean Population
      Hae Woo, Jeonghee Lee, Il Choi, Chan Kim, Jong Lee, Oran Kwon, Jeongseon Kim
      Nutrients.2014; 6(11): 4961.     CrossRef

    • PubReader PubReader
    • ePub LinkePub Link
    • Cite
      CITE
      export Copy Download
      Close
      Download Citation
      Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.
      Format:
      • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
      • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
      Include:
      • Citation for the content below
      Prediction of Cancer Incidence and Mortality in Korea, 2014
      Cancer Res Treat. 2014;46(2):124-130.   Published online April 15, 2014
      DOI: https://doi.org/10.4143/crt.2014.46.2.124
      Close
    • XML DownloadXML Download
    Figure
    • 0
    • 1
    • 2
    Related articles
    Prediction of Cancer Incidence and Mortality in Korea, 2014
    Image Image Image
    Fig. 1 The 10 leading types of estimated new cancer cases and deaths by sex in 2014. (A) Estimated new cases. (B) Estimated deaths.
    Fig. 2 Projected age-specific incidences of major cancers during 2014 in Korea. (A) Male. (B) Female.
    Fig. 3 Projected age-specific mortality rates of major cancers during 2014 in Korea. (A) Male. (B) Female.

    Fig. 1

    Fig. 2

    Fig. 3

    Prediction of Cancer Incidence and Mortality in Korea, 2014
    Site Estimated new cases Estimated deaths
    Both Male Female Both Male Female
    All sites 265,813 131,455 134,358 74,981 46,653 28,328
    Lip, oral cavity, and pharynx 3,059 2,254 805 1,037 763 274
    Esophagus 2,313 2,125 188 1,215 1,135 80
    Stomach 34,478 23,471 11,007 7,876 5,056 2,820
    Colon and rectum 36,125 22,304 13,821 8,746 5,048 3,698
    Liver 17,182 12,654 4,528 10,761 8,017 2,744
    Gallbladdera) 5,841 2,918 2,923 3,962 1,912 2,050
    Pancreas 5,935 3,185 2,750 5,133 2,697 2,436
    Larynx 1,063 1,029 34 374 367 7
    Lung 24,697 17,139 7,558 16,990 12,346 4,644
    Breast 18,456 74 18,382 2,162 17 2,145
    Cervix uteri 3,205 - 3,205 784 - 784
    Corpus uteri 2,319 - 2,319 277 - 277
    Ovary 2,271 - 2,271 1,020 - 1,020
    Prostate 13,650 13,650 - 1,706 1,706 -
    Testis 233 233 - 19 19 -
    Kidney 4,904 3,376 1,528 978 671 307
    Bladder 4,173 3,358 815 1,264 945 319
    Brain and CNS 1,867 995 872 1,118 593 525
    Thyroid 59,516 9,912 49,604 373 114 259
    Hodgkin lymphoma 283 182 101 54 36 18
    Non-Hodgkin lymphoma 5,021 2,748 2,273 1,584 917 667
    Multiple myeloma 1,368 733 635 876 476 400
    Leukemia 3,063 1,721 1,342 1,737 999 738
    Other and ill-defined 14,791 7,394 7,397 4,935 2,819 2,116
    Site Crude incidence rate per 100,000 Age-standardized incidence rate per 100,000a)
    Both Male Female Both Male Female
    All sites 524.7 519.0 530.4 338.5 358.4 338.3
    Lip, oral cavity, and pharynx 6.0 8.9 3.2 4.0 6.1 2.1
    Esophagus 4.6 8.4 0.7 2.8 5.7 0.4
    Stomach 68.1 92.7 43.5 42.1 62.7 24.8
    Colon and rectum 71.3 88.1 54.6 44.1 60.1 30.5
    Liver 33.9 50.0 17.9 21.0 33.6 9.8
    Gallbladderb) 11.5 11.5 11.5 6.6 7.9 5.6
    Pancreas 11.7 12.6 10.9 6.8 8.5 5.4
    Larynx 2.1 4.1 0.1 1.3 2.7 0.1
    Lung 48.8 67.7 29.8 28.4 45.6 15.6
    Breast 36.4 0.3 72.6 24.4 0.2 48.5
    Cervix uteri 6.3 - 12.7 4.2 - 8.2
    Corpus uteri 4.6 - 9.2 3.0 - 6.0
    Ovary 4.5 - 9.0 3.1 - 6.1
    Prostate 26.9 53.9 - 16.2 36.9 -
    Testis 0.5 0.9 - 0.5 0.9 -
    Kidney 9.7 13.3 6.0 6.4 9.2 3.8
    Bladder 8.2 13.3 3.2 4.7 8.9 1.5
    Brain and CNS 3.7 3.9 3.4 3.0 3.4 2.7
    Thyroid 117.5 39.1 195.8 82.6 27.6 138.3
    Hodgkin lymphoma 0.6 0.7 0.4 0.5 0.6 0.4
    Non-Hodgkin lymphoma 9.9 10.9 9.0 6.9 8.1 5.9
    Multiple myeloma 2.7 2.9 2.5 1.6 2.0 1.4
    Leukemia 6.1 6.8 5.3 5.3 6.2 4.5
    Other and ill-defined 29.2 29.2 29.2 19.0 21.4 17.1
    Rank Age group (yr)
    0-14 15-34 35-64 ≥65
    Male
     1 Leukemia Thyroid Stomach Lung
      (5.2) (17.1) (102.6) (475.1)
     2 Brain and CNS Colon and rectum Colon and rectum Stomach
      (2.4) (3.4) (96.2) (444.1)
     3 Non-Hodgkin lymphoma Leukemia Thyroid Colon and rectum
      (2.2) (3.3) (66.3) (425.0)
     4 Kidney Non-Hodgkin lymphoma Liver Prostate
      (0.6) (3.2) (63.6) (399.4)
     5 Liver/Testis Stomach Lung Liver
    (0.3) (2.4) (42.4) (201.5)
    Female
     1 Leukemia Thyroid Thyroid Colon and rectum
      (4.3) (89.4) (343.4) (210.9)
     2 Brain and CNS Breast Breast Stomach
      (2.0) (11.9) (131.9) (156.9)
     3 Non-Hodgkin lymphoma Cervix uteri Colon and rectum Lung
      (1.2) (5.4) (52.8) (135.2)
     4 Ovary Stomach Stomach Thyroid
      (0.8) (4.0) (44.5) (120.5)
     5 Thyroid Ovary Lung Liver
      (0.7) (2.9) (23.1) (78.9)
    Site/Type Crude mortality rate per 100,000 Age-standardized mortality rate per 100,000a)
    Both Male Female Both Male Female
    All sites 148.0 184.2 111.8 84.6 125.7 55.3
    Lip, oral cavity, and pharynx 2.1 3.0 1.1 1.2 2.0 0.6
    Esophagus 2.4 4.5 0.3 1.4 3.0 0.1
    Stomach 15.6 20.0 11.1 8.7 13.6 5.2
    Colon and rectum 17.3 19.9 14.6 9.7 13.7 6.7
    Liver 21.2 31.7 10.8 12.7 21.4 5.4
    Gallbladderb) 7.8 7.6 8.1 4.2 5.2 3.6
    Pancreas 10.1 10.7 9.6 5.7 7.2 4.5
    Larynx 0.7 1.5 0.0 0.4 1.0 0.0
    Lung 33.5 48.7 18.3 18.6 32.7 8.5
    Breast 4.3 0.1 8.5 2.7 0.1 5.2
    Cervix uteri 1.6 - 3.1 0.9 - 1.7
    Corpus uteri 0.6 - 1.1 0.3 - 0.6
    Ovary 2.0 - 4.0 1.2 - 2.3
    Prostate 3.4 6.7 - 1.7 4.8 -
    Testis 0.0 0.1 - 0.0 0.1 -
    Kidney 1.9 2.7 1.2 1.1 1.8 0.6
    Bladder 2.5 3.7 1.3 1.3 2.6 0.5
    Brain and CNS 2.2 2.3 2.1 1.6 1.8 1.3
    Thyroid 0.7 0.5 1.0 0.4 0.3 0.4
    Hodgkin lymphoma 0.1 0.1 0.1 0.1 0.1 0.0
    Non-Hodgkin lymphoma 3.1 3.6 2.6 1.8 2.5 1.3
    Multiple myeloma 1.7 1.9 1.6 1.0 1.3 0.8
    Leukemia 3.4 3.9 2.9 2.3 2.9 1.8
    Other and ill-defined 9.7 11.1 8.4 5.6 7.7 4.1
    Table 1 Estimated new cancer cases and deaths by sex during 2014 in Korea

    CNS, central nervous system.

    Includes the gallbladder and other/unspecified parts of the biliary tract.

    Table 2 Estimated crude and age-standardized cancer incidences by sex during 2014 in Korea

    CNS, central nervous system.

    Age adjusted to the world standard population,

    Includes the gallbladder and other/unspecified parts of the biliary tract.

    Table 3 Estimated cancer incidence by age group and sex during 2014 in Korea

    CNS, central nervous system.

    Table 4 Estimated crude and age-standardized cancer mortality rates by sex during 2014 in Korea

    CNS, central nervous system.

    Age adjusted to the world standard population,

    Includes the gallbladder and other/unspecified parts of the biliary tract.

    Table 1

    Table 2

    Table 3

    Table 4

    Cancer Res Treat : Cancer Research and Treatment
    © Korean Cancer Association.
    Close layer
    TOP